glp 1 receptor agonist GLP-1 agonists show promise in treating substance use disorders Exploring the Side Effects of
Description
Semaglutide versus dulaglutide once weekly in patients with type 2 diabetes (SUSTAIN 7): a randomised, openlabel, phase 3b trial
However, these medications also face several challenges, including low stability in the body, short half-lives, poor membrane permeability, complex manufacturing processes, and high costs
D., Sun, T
Physicians must conduct thorough screenings that account for contraindications including a history of pancreatitis, thyroid cancer, and eating disorders
BMC Public Health
doi: 10.1016/j.brainres.2018.04.031 207 WilkinsonM
